Version 3.0.0 · 2026-11-13
House notes
The public site sells a routine. This page is the plan that decided the routine. Numbers name their sources. Where two publishers disagree, both stay.
Names
Maereth is the name on the site. Halveth is a live soap shop, so it was left behind. Calemere was left unused.
Manufacturer
Target percentages, the claims matrix, bone glass, copper, and four Veil shade lists.
What version 1 was for
- 01
Pick the audience from the Census, not from a persona workshop.
- 02
Let concern share and search direction choose the six formulas.
- 03
Price a four-step set a woman in her thirties will finish.
- 04
Write pages an answer engine can quote without inheriting a drug claim.
- 05
Show the white-label economics before a factory is signed.
- 06
Ship a brand system strong enough to judge the next round against.
Audience
69,437,978 U.S. women, ages 20 through 50, on 2025-07-01. That is 22,746,630 in the twenties, 23,184,009 in the thirties, and 23,507,339 from 40 through 50.
U.S. Census Bureau, Population Estimates Program, Vintage 2025, NC-EST2025-AGESEX-RES.
Grand View's adults segment was the largest age band in 2025, at 38.2 percent. Women were 66.1 percent of category revenue. The house does not chase teens, and it does not pretend fifty-one and eighty are the same brief. The top of our band is fifty because that is where the routine still shares jars with the thirties.
Market, without averaging the fight
| Source | What they measured | Figure |
|---|---|---|
| Grand View | U.S. skin care products, 2025 / 2026 / 2033 | $35.6B / $38B / $62.9B |
| Grand View | CAGR, 2026–2033 | 7.5% |
| Statista | Narrower skin-care outlook, 2025 | $26.01B, 3.72% CAGR |
| Circana | Prestige skincare, Jan–Sep 2026 | $7.4B, +7%, units up double digits |
We plan off Grand View when we need a wide products market, and off orders when we need a forecast. Statista stays on the page so nobody “reconciles” a 35.6 and a 26.01 into a fake midpoint.
Why these formulas
- Signal. Peptides led Statista's early-2026 ingredient ranking. LookFantastic saw peptide searches up 79 percent in 2025. Niacinamide interest among women who were not yet buyers was 58 percent.
- Vesper. 71 percent of women wanted a retinol alternative they were not using. Retinal searches were up about 50 percent in that same retailer read.
- Seam. Barrier-building is Mintel's first 2026 territory. 65 percent of women were interested in a barrier cream.
- Veil. SPF was the fastest-growing skin and body category in the LookFantastic report, and sun-damage searches were up 66.6 percent from 2024. The tint is how a mineral screen gets used on more than one depth of skin.
The LookFantastic figures are a U.K. retailer's search read. They are a direction, not U.S. volume.
Orders, not a share of a billion
A $48 cost to acquire a new buyer, The Four as a third of orders, and Veil pulling people back at week six.
Blended order $90.94 · pilot COGS $12.19 before freight · 1.96 units per order.
| Year | Orders | Revenue | Contribution | Operating |
|---|---|---|---|---|
| Year 1 | 3,600 | $327,384 | $137,100 | $32,100 |
| Year 2 | 9,000 | $818,460 | $461,034 | $293,034 |
| Year 3 | 18,000 | $1,636,920 | $1,036,728 | $796,728 |
Contribution is revenue minus landed COGS, fulfillment, payment fees, and paid acquisition. Operating subtracts fixed cost. Launch capital of $150,440 sits outside operating profit. On this scenario, year 1 cash after that outlay is -$118,340.
Launch capital
- Six formulation briefs$48,000
- SPF monograph testing, stability, and panel$28,000
- Component tooling and first print$12,000
- Opening inventory at pilot COGS$36,440
- Identity, photography, entity, insurance, trademark filing$18,000
- Samples and creator seeding$8,000
- Cash to first sellable batch$150,440
Scale check
69,437,978 women, ages 20–50, on 1 July 2025.
Three years of base orders are 0.044% of that audience. Illustrative women's face care in 2026, if Grand View's 2025 face and women shares apply to the 2026 total, is $17.76 billion. The house does not plan as a share of that number. It plans in orders.
Online, in the order it pays
- 1. The quiz and The Four. Conversion before content scale. A completed edit is the only on-site “scan.”
- 2. Pages that match buyer phrases. Tinted sunscreen, peptide serum, dark spot corrector, ceramide moisturizer. Head terms like “sunscreen” and “serum” are context, not the media buy.
- 3. Answer engines. First paragraphs define the thing and the limit. FAQ, product, and article schema. An llms.txt file states the entity. We do not publish a fake clinical percentage an engine might repeat.
- 4. Creators from 28 to 48, across depths of skin. A 28-day seam diary. Seeding is in the launch capital. Discount codes come after the diary, not before.
- 5. Veil as the reorder. About six weeks of daily face use. That replenishment is the subscription, once a card exists.
- 6. Wholesale later. Not Sephora in year one. A 50 percent wholesale price still clears pilot COGS. It waits until repeat purchase is real.
Keyword map
Theseolabs skincare keyword list, retrieved 2026-11-13. Monthly searches and CPC are their rounded figures. A live Google Keyword Planner or Ahrefs export was not available on this date. The table stays the public Theseolabs list. Do not plan media on these volumes.
| Phrase | Monthly | CPC | Page |
|---|---|---|---|
retinol Ingredient research. We answer with retinal, the alternative 71% of women said they wanted to try. | 165,000 | $3.00 | /journal/retinal-and-retinol |
niacinamide Ingredient research. Signal and Kindling both state 5%. | 165,000 | $2.07 | /science/niacinamide |
melasma Medical term. The page refuses to treat it and routes changing spots to a dermatologist. | 165,000 | $4.01 | /journal/dark-spots |
hyaluronic acid Crowded head term. We do not bid it. The page explains why beta-glucan is the humectant in Signal. | 246,000 | $1.42 | /science/beta-glucan |
hyperpigmentation High commercial intent. Cosmetic language only. | 135,000 | $4.01 | /journal/dark-spots |
sunscreen Head term. Veil owns the tinted mineral slice, not the whole category. | 110,000 | $4.47 | /shop/veil |
peptides Top-ranked ingredient search in early 2026 on Statista's public note. Hero product. | 90,500 | $6.69 | /science/peptides |
vitamin c serum We do not launch a vitamin C in batch 01. The page says why tone is Kindling instead. | 90,500 | $2.89 | /journal/dark-spots |
skin care routine Routine builders. The Four is the answer. | 60,500 | $4.59 | /regimen |
moisturizer Head term. Seam is the ceramide seal, not a body lotion. | 60,500 | $4.52 | /shop/seam |
serum Generic. Signal is the page that should rank for the modifier, not the head. | 49,500 | $4.06 | /shop/signal |
tinted sunscreen Best commercial fit on the map. Higher CPC than mineral sunscreen. | 22,200 | $4.54 | /shop/veil |
mineral sunscreen Education that sells Veil without pretending one tint fits every depth. | 22,200 | $2.80 | /journal/tinted-mineral-spf |
ceramides Barrier cluster. Seam. | 22,200 | $3.78 | /science/ceramides |
dark spot corrector Buyer language. Kindling's title uses it. | 14,800 | $4.24 | /shop/kindling |
skin barrier repair Smaller volume, high fit, and the Mintel territory we are built on. | 4,400 | $4.14 | /journal/skin-barrier |
skin barrier Supporting query for the same essay. | 3,600 | $2.98 | /journal/skin-barrier |
This version
- New photographs for the hero, the six formulas, four Veil depths, and three decades.
- The header is Shop, The Four, Journal, and the bag. Veil cannot be reserved without a named shade.
- The Four is $168 on the home page, and an empty bag no longer guesses Sand.
Still open
- A counsel search of TSDR before an application is filed or a die is cut.
- A signed U.S. OTC lab, a released drug panel, and only then a card charge.
- A dated Keyword Planner or Ahrefs export before any media is planned.